Table 6.

Recommended ruxolitinib starting dose for patients with cGVHD.

Setting	Ruxolitinib Dose
Usual starting dose	10 mg twice daily
Modifications for use with CYP3A4 inhibitors
Fluconazole doses of less than or equal to 200 mg	5 mg twice daily
Other CYP3A4 inhibitors	Monitor blood counts more frequently for toxicity and modify the ruxolitinib dosage for adverse reactions if they occur
Modification for renal impairment
Moderate (CLcr 30 to 59 mL/minute) or severe (CLcr 15 to 29 mL/minute)	5 mg twice daily
ESRD (CLcr <15 mL/minute) on dialysis	10 mg once after dialysis session
Modification for hepatic disease
Mild, moderate, or severe based on NCI criteria without liver GVHD	No dose adjustment
Score 1 or 2 liver cGVHD	No dose adjustment
Score 3 liver cGVHD	Monitor blood counts more frequently for toxicity and modify the ruxolitinib dosage for adverse reactions if they occur

Adapted from the US Prescribing Information dated September 2021.

Abbreviations: cGVHD, chronic graft-versus-host disease; CLCr, creatinine clearance.